I-Mab IMAB
2.88 0.00 (+0.00%)
Mar 17, 2026, 9:30 AM EDT
2.81 Day range 3.01
52-week range unavailable
- YTD
- +238.82%
- 1 year
- +144.07%
News
marketbeat.com I-Mab Picks Givastomig Dose After Promising Gastric Cancer Data, Aligns With FDA I-Mab NASDAQ: NBP presented updated Phase 1b data for givastomig, an investigational treatment being developed for frontline metastatic gastric and gastroesophageal cancer, citing longer follow-up…
globenewswire.com I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide Strategy centers on broadening access to global…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of I-Mab ("I-Mab" or the "Company") (NASDAQ: IMAB). Such investors are advised to contact…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of I-Mab ("I-Mab" or the "Company") (NASDAQ: IMAB). Such investors are advised to contact…
globenewswire.com I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025 ROCKVILLE, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), is a global biotechnology platform company committed to accelerating access to innovative medicines for…
seekingalpha.com I-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth Transcript I-Mab (NASDAQ:IMAB ) Discusses Business Transformation Strategy and Plans for Accelerated Growth October 16, 2025 5:00 PM EDT Company Participants Xi-Yong Fu - CEO & Director Wei Fu - Executive…
globenewswire.com I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), a global biotechnology platform company committed to accelerating access to innovative medicines for…
globenewswire.com I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 22-26 in Boston, Massachusetts ROCKVILLE, Md. , Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
zacks.com I-Mab Sponsored ADR (IMAB) Is Up 24.14% in One Week: What You Should Know Does I-Mab Sponsored ADR (IMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
benzinga.com Dell, Select Medical, Century Aluminum And Other Big Stocks Moving Higher On Wednesday 
zacks.com What Makes IMab (IMAB) a New Buy Stock IMab (IMAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
benzinga.com This Bank of New York Mellon Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Wolfspeed Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket 
seekingalpha.com I-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By Market I-Mab has pivoted to focus on givastomig for gastric cancer, after divesting its original China portfolio and revamping leadership. Givastomig shows superior early efficacy versus rivals, with…
benzinga.com C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
zacks.com Are You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great Choice Does I-Mab Sponsored ADR (IMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
globenewswire.com I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee ROCKVILLE, Md., Aug. 25, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the…
benzinga.com Hewlett Packard Enterprise To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday 
globenewswire.com I-Mab to Participate in September Investor Conferences ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the…
benzinga.com Evolv Technologies, Precigen, Hesai Group And Other Big Stocks Moving Higher On Friday 
benzinga.com Kimball Electronics Posts Better-Than-Expected Earnings, Joins Terawulf, Dlocal, Equinox Gold And Other Big Stocks Moving Higher On Thursday - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
prnewswire.com Everest Medicines Expands Strategic Investment in I-MAB - Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%.
globenewswire.com I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares ROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
globenewswire.com I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health ROCKVILLE, Md., July 17, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
globenewswire.com I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or…
globenewswire.com I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research Monotherapy efficacy and safety profile provided backbone for clinical development strategy in 1L combination with nivolumab plus chemotherapy
globenewswire.com I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across doses selected for ongoing dose expansion study Responses observed in…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com ADT To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Friday - benzinga.com Stocks That Hit 52-Week Lows On Monday Monday's session saw 175 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 225 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 283 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 179 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 210 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 201 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 155 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's trading, 188 companies set new 52-week lows.